β-defensin 11 Inhibitors
β-Defensin 11, a crucial component of the innate immune system, produces antimicrobial peptides essential for host defense. The inhibitors listed above target specific pathways and molecules associated with β-defensin 11 expression, either directly or indirectly modulating its activity. BAY 11-7082 directly inhibits nuclear factor-kappa B (NF-κB), a transcription factor involved in the regulation of β-defensin 11, disrupting the transcriptional control of antimicrobial peptides. LY294002 and Rapamycin target phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), respectively, influencing the PI3K/Akt pathway crucial for β-defensin 11 regulation. Tofacitinib inhibits Janus kinase (JAK), interfering with the JAK-STAT pathway crucial for β-defensin 11 regulation. SB203580 inhibits p38 mitogen-activated protein kinase (MAPK), disrupting the MAPK signaling pathway crucial for β-defensin 11 regulation. U0126 inhibits mitogen-activated protein kinase kinase (MEK), indirectly disrupting β-defensin 11 expression.
SP600125 inhibits activator protein-1 (AP-1), directly interfering with the transcriptional control of β-defensin 11. Triciribine inhibits Akt in the PI3K/Akt pathway, indirectly influencing β-defensin 11 expression. BMS-345541 inhibits the IKK complex, directly blocking NF-κB activation and suppressing the transcriptional regulation of β-defensin 11. SB216763 inhibits glycogen synthase kinase-3 (GSK-3), indirectly modulating β-defensin 11 expression. GDC-0068 inhibits Akt in the PI3K/Akt pathway, indirectly influencing β-defensin 11 expression. sc-514 inhibits IkB kinase-2 (IKK-2), directly blocking NF-κB activation and suppressing the transcriptional regulation of β-defensin 11. In summary, these inhibitors offer a comprehensive approach to directly or indirectly interfere with β-defensin 11 activity by strategically targeting key components within its signaling pathways. They provide valuable tools for studying the intricate regulation of antimicrobial peptides, including β-defensins, and the innate immune response.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Blocks the activation of nuclear factor-kappa B (NF-κB), a transcription factor involved in the regulation of β-defensin 11. By inhibiting NF-κB, this compound directly interferes with the transcriptional control of antimicrobial peptides, including β-defensin 11. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inhibits phosphoinositide 3-kinase (PI3K), a kinase involved in the PI3K/Akt pathway. Indirectly influences β-defensin 11 expression by disrupting the signaling cascade that regulates antimicrobial peptides, including β-defensins. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mammalian target of rapamycin (mTOR), a component in the PI3K/Akt pathway. Indirectly modulates β-defensin 11 expression by suppressing mTOR, a kinase crucial for the regulation of antimicrobial peptides, including β-defensins. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Inhibits p38 mitogen-activated protein kinase (MAPK), a component in the MAPK signaling pathway. Indirectly disrupts β-defensin 11 expression by suppressing p38 MAPK, a kinase involved in the regulation of antimicrobial peptides, including β-defensins. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits activator protein-1 (AP-1), a transcription factor involved in the regulation of β-defensin 11. By blocking AP-1 activation, this compound directly interferes with the transcriptional control of antimicrobial peptides, including β-defensin 11. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Inhibits Akt, a kinase in the PI3K/Akt pathway. Indirectly influences β-defensin 11 expression by suppressing Akt, a kinase crucial for the regulation of antimicrobial peptides, including β-defensins. | ||||||
BMS-345541 | 445430-58-0 | sc-221741 | 1 mg | $312.00 | 1 | |
Inhibits the IKK complex, directly blocking NF-κB activation. By targeting IKK, it indirectly hinders β-defensin 11 expression, as NF-κB regulates the transcription of antimicrobial peptides, including β-defensins. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
Inhibits glycogen synthase kinase-3 (GSK-3), a kinase involved in the regulation of β-defensin 11. Indirectly modulates β-defensin 11 expression by suppressing GSK-3, a kinase crucial for the regulation of antimicrobial peptides, including β-defensins. | ||||||
(2S)-2-(4-Chlorophenyl)-1-[4-[(5R,7R)-6,7-dihydro-7-hydroxy-5-methyl-5H-cyclopentapyrimidin-4-yl]-1-piperazinyl]-3-[(1-methylethyl)amino]-1-propanone | sc-501166 | 5 mg | $540.00 | |||
Inhibits Akt, a kinase in the PI3K/Akt pathway. Indirectly influences β-defensin 11 expression by suppressing Akt, a kinase crucial for the regulation of antimicrobial peptides, including β-defensins. | ||||||
SC514 | 354812-17-2 | sc-205504 sc-205504A | 5 mg 10 mg | $67.00 $91.00 | 13 | |
Inhibits IkB kinase-2 (IKK-2), directly blocking NF-κB activation. By inhibiting IKK-2, it indirectly hinders β-defensin 11 expression, as NF-κB regulates the transcription of antimicrobial peptides, including β-defensins. | ||||||